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Factor H genotype–phenotype 
correlations: lessons from aHUS, 
MPGN II, and AMD
THJ Goodship1
Missense mutations in the  C-terminal region of  Factor H are 
associated with atypical hemolytic uremic syndrome, whereas 
homozygous Factor H deficiency is more frequently associated with 
membranoproliferative glomerulonephritis type II (MPGN II). The 
report of Licht et al. of a mutation in the complement-regulatory 
N-terminal region of Factor H in  MPGN II provides additional insight 
into the pathogenesis of this condition.
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Factor H is a soluble complement regu-
lator produced by the liver. It has a piv-
otal role in regulating the activity of the 
alternative pathway. Th e gene encoding 
Factor H (CFH) lies within the regula-
tion of complement activation (RCA) 
gene cluster at 1q32. Th e secreted pro-
tein product of CFH consists of 20 
repetitive units (each ~60 amino acids) 
named short consensus repeats (SCRs) 
or complement control protein modules. 
Within each SCR there are four conserved 
cysteine residues that form two disulfi de 
bridges essential for structural integrity. 
Th e 20 SCRs of Factor H are encoded by 
22 exons. Factor H downregulates the 
activity of the alternative complement 
pathway by increasing the rate of disso-
ciation of the alternative pathway conver-
tase C3bBb (decay-accelerating activity) 
and by acting as a cofactor for the ser-
ine protease Factor I, which cleaves C3b 
(cofactor activity). In addition, Factor H 
is able to inactivate membrane-bound 
C3b by binding to anionic residues on 
cell surfaces and basement membrane. 
Th e complement-regulatory activity of 
Factor H is localized in the N-terminal 
region (SCRs 1–4), and the cell-binding 
activity is localized in the C-terminal 
region (SCRs 19 and 20). Th ere is also 
additional C3b- and heparin-binding 
activity located in SCRs 12–14. 
In the late 1990s, a series of reports 
showed an association between CFH 
mutations and atypical hemolytic uremic 
syndrome (aHUS).1 Th e majority of these 
mutations are heterozygous missense 
changes in which the Factor H concentra-
tion is normal. Th ese mutations cluster in 
the exons encoding SCRs 19 and 20, and 
functional studies have shown impaired 
C3b and heparin binding. aHUS is also 
associated with defi ciency of Factor H. In 
the majority of cases this is heterozygous, 
and a range of mutations throughout the 
gene have been reported. Many of these 
aff ect the invariant cysteine residues. In 
contrast, homozygous Factor H defi-
ciency is usually associated with mem-
branoproliferative glomerulonephritis 
type II (MPGN II).2 
There are two animal models of 
Factor H deficiency. The Norwegian 
Yorkshire pig has a point mutation 
(T3610G) in the exon encoding SCR 20, 
which results in an isoleucine-to-arginine 
change (I1166R). Th is presumably results 
in impaired secretion. Homozygous 
animals die from renal failure within 
11 days of birth. Histologically they have 
the characteristic features of MPGN II. 
These changes are already present in 
utero, with deposits of C3 and the termi-
nal complement complex visible within 
the glomerular basement membrane. 
Through selective breeding, this dis-
ease has now been eradicated from the 
Norwegian Yorkshire pig. Targeted dele-
tion of Cfh  in the mouse also results in 
the development of MPGN II but with 
only a 25% mortality at 8 months.3 Th at 
uncontrolled activation of the alterna-
tive pathway is essential for the develop-
ment of MPGN in the Cfh –/– mouse was 
shown through the introduction of a sec-
ond mutation in the Factor B gene. Th e 
double homozygote (Cfh –/–; Bf–/–) did not 
develop MPGN. 
Th e report of Licht et al.4 (this issue) 
signifi cantly extends these observations. 
CFH mutation screening in two sibs 
(products of a consanguineous marriage) 
with MPGN II showed a homozygous 
3-bp deletion (743–745del) leading to 
the deletion of a lysine residue (K224del) 
in SCR 4. Because Factor H was detect-
able in the serum of the two sibs, albeit 
at slightly lower levels than normal, one 
can assume that the mutant protein is 
secreted. Functional analyses showed 
defective C3b binding, cofactor activ-
ity, and decay-accelerating activity. To 
my knowledge this is the fi rst published 
report of a secreted mutant Factor H with 
impaired regulatory activity in associa-
tion with MPGN II. 
It is of interest that both sibs and their 
mother were positive for C3NeF, which 
is found in over 80% of patients with 
MPGN II and to a lesser extent in patients 
with MPGN I and III. C3NeF is an immu-
noglobulin G autoantibody directed 
against C3bBb, the alternative pathway 
convertase. It slows both the spontane-
ous and the Factor H-mediated decay of 
the convertase, thus increasing the activ-
ity of the alternative pathway. Th ere has 
been debate as to the role of C3NeF in the 
pathogenesis of MPGN II. Some consider 
it to be an epiphenomenon, whereas oth-
ers believe it is nephritogenic.5 Th e evi-
dence from the CFH knockout mouse 
suggests that uncontrolled activation 
of the alternative pathway is pivotal in 
the development of MPGN II. C3NeF, 
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through its action on the convertase, 
undoubtedly leads to loss of control of the 
alternative pathway. However, the origin 
of C3NeF is a conundrum.6 It has been 
suggested that it is produced in everyone 
from the time of birth but is controlled 
by the idiotypic network. Loss of control 
of the network or inappropriate stimula-
tion might lead to the continuing pres-
ence of C3NeF. Th at the patients in the 
study by Licht et al.4 had both a function-
ally signifi cant CFH mutation and C3NeF 
does raise the possibility that hereditary 
systemic dysregulation of the alterna-
tive pathway predisposes to the presence 
of C3NeF. CFH mutation screening of 
patients known to have C3NeF may pro-
vide an answer to this question.
Patients with MPGN II also develop 
ocular lesions similar to the drusen 
seen in age-related macular degenera-
tion (AMD). A series of recent studies 
have shown that CFH alleles act as a 
susceptibility factor for AMD. In par-
ticular, a polymorphism in CFH exon 9 
(rs1061170; 1277T>C) associated with a 
tyrosine-to-histidine change (Y402H) has 
been shown to be a susceptibility factor in 
all these studies. Functionally, SCR 7 is a 
binding site for heparin and C-reactive 
protein; whether Y402H is functionally 
signifi cant remains to be established. One 
of these recent studies has also shown that 
MPGN II and AMD patients share several 
CFH risk alleles.7 Th us, naturally occur-
ring variability in CFH acts as a suscepti-
bility factor for MPGN II. It has also been 
established in four independent cohorts 
that CFH alleles act as a susceptibility 
factor for the development of aHUS.8 
However, the risk alleles for AMD and 
MPGN II are not the same as for aHUS. 
For instance, Y402H is not a susceptibil-
ity allele in aHUS. Th us, diff erent CFH 
alleles are associated with predisposition 
to a diff erent phenotype. In aHUS, CFH 
has been found to be not only a suscep-
tibility factor but also the gene encoding 
the transmembrane complement regula-
tor membrane cofactor protein (MCP; 
CD46). MCP is widely expressed and 
has cofactor activity for both the classical 
and the alternative pathway. In addition, 
functionally signifi cant MCP mutations 
have been described in aHUS.9
Complement genes within the regu-
lation of complement activation (RCA) 
cluster are arranged in tandem in two 
groups. In a centromeric 360-kb segment 
lie CFH and the genes for fi ve Factor H-
related proteins — CFHL1–CFHL5 (ali-
ases FHR1–FHR5). Th ere is a high degree 
of sequence identity between CFH and 
CFHL1–CFHL5, and it has been reported 
that allelic variants of CFHL5 are asso-
ciated with MPGN II.10 Th e serum con-
centrations of the fi ve Factor H-related 
proteins are signifi cantly lower than that 
of Factor H, and their role in complement 
regulation is uncertain.
In conclusion, there have been impor-
tant advances in the past decade in our 
understanding of the phenotype associ-
ated with mutations and polymorphisms 
in Factor H. Th ere are undoubtedly more 
to come.
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